Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 494

1.

Photon iso-effective dose for cancer treatment with mixed field radiation based on dose-response assessment from human and an animal model: clinical application to boron neutron capture therapy for head and neck cancer.

Gonzalez SJ, Pozzi ECC, Monti Hughes A, Provenzano L, Koivunoro H, Carando DG, Thorp SI, Casal MR, Bortolussi S, Trivillin VA, Garabalino MA, Curotto P, Heber EM, Santa Cruz GA, Kankaanranta L, Joensuu H, Schwint AE.

Phys Med Biol. 2017 Aug 31. doi: 10.1088/1361-6560/aa8986. [Epub ahead of print]

PMID:
28858854
2.

CD73 promotes resistance to HER2/ErbB2 antibody therapy.

Turcotte M, Allard D, Mittal D, Bareche Y, Buisseret L, Jose V, Pommey S, Delisle V, Loi S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Smyth MJ, Stagg J.

Cancer Res. 2017 Aug 30. pii: canres.0707.2017. doi: 10.1158/0008-5472.CAN-17-0707. [Epub ahead of print]

PMID:
28855210
3.

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.

Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A.

Br J Cancer. 2017 Aug 29. doi: 10.1038/bjc.2017.290. [Epub ahead of print]

PMID:
28850565
4.

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.

Fizazi K, Massard C, Bono P, Kataja V, James N, Tammela TL, Joensuu H, Aspegren J, Mustonen M.

Eur Urol Focus. 2017 Feb 27. pii: S2405-4569(17)30019-6. doi: 10.1016/j.euf.2017.01.010. [Epub ahead of print]

5.

Plasma levels of hepatocyte growth factor and placental growth factor predict mortality in a general population: a prospective cohort study.

Santalahti K, Havulinna A, Maksimow M, Zeller T, Blankenberg S, Vehtari A, Joensuu H, Jalkanen S, Salomaa V, Salmi M.

J Intern Med. 2017 Oct;282(4):340-352. doi: 10.1111/joim.12648. Epub 2017 Jul 31.

PMID:
28682476
6.

An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.

Varga Z, Lebeau A, Bu H, Hartmann A, Penault-Llorca F, Guerini-Rocco E, Schraml P, Symmans F, Stoehr R, Teng X, Turzynski A, von Wasielewski R, Gürtler C, Laible M, Schlombs K, Joensuu H, Keller T, Sinn P, Sahin U, Bartlett J, Viale G.

Breast Cancer Res. 2017 May 11;19(1):55. doi: 10.1186/s13058-017-0848-z.

7.

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL.

Clin Cancer Res. 2017 Aug 1;23(15):4323-4334. doi: 10.1158/1078-0432.CCR-16-2287. Epub 2017 Apr 5.

PMID:
28381415
8.

SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour.

Pulkka OP, Nilsson B, Sarlomo-Rikala M, Reichardt P, Eriksson M, Hall KS, Wardelmann E, Vehtari A, Joensuu H, Sihto H.

Br J Cancer. 2017 Apr 25;116(9):1195-1202. doi: 10.1038/bjc.2017.82. Epub 2017 Mar 23.

9.

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.

Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P.

JAMA Oncol. 2017 May 1;3(5):602-609. doi: 10.1001/jamaoncol.2016.5751.

PMID:
28334365
10.

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Lahdenperä O, Kosonen S, Villman K, Nyandoto P, Nilsson G, Poikonen-Saksela P, Kataja V, Junnila J, Bono P, Lindman H.

JAMA Oncol. 2017 Jun 1;3(6):793-800. doi: 10.1001/jamaoncol.2016.6120.

PMID:
28253390
11.

Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib.

Peltola KJ, Penttilä P, Rautiola J, Joensuu H, Hänninen E, Ristimäki A, Bono P.

Clin Genitourin Cancer. 2017 Aug;15(4):487-494. doi: 10.1016/j.clgc.2017.01.021. Epub 2017 Feb 1.

PMID:
28237182
12.

Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects.

Gilbert ES, Curtis RE, Hauptmann M, Kleinerman RA, Lynch CF, Stovall M, Smith SA, Weathers R, Andersson M, Dores GM, Fraumeni JF Jr, Fossa SD, Hall P, Hodgson DC, Holowaty EJ, Joensuu H, Johannesen TB, Langmark F, Kaijser M, Pukkala E, Rajaraman P, Storm HH, Vaalavirta L, van den Belt-Dusebout AW, Aleman BM, Travis LB, Morton LM, van Leeuwen FE.

Radiat Res. 2017 Feb;187(2):186-195. doi: 10.1667/RR14453.1. Epub 2017 Jan 24.

PMID:
28118119
13.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Joensuu H.

N Engl J Med. 2016 Oct 20;375(16):1592. doi: 10.1056/NEJMc1609993. No abstract available.

PMID:
28103001
14.

L-type calcium channels regulate filopodia stability and cancer cell invasion downstream of integrin signalling.

Jacquemet G, Baghirov H, Georgiadou M, Sihto H, Peuhu E, Cettour-Janet P, He T, Perälä M, Kronqvist P, Joensuu H, Ivaska J.

Nat Commun. 2016 Dec 2;7:13297. doi: 10.1038/ncomms13297.

15.

Escalating and de-escalating treatment in HER2-positive early breast cancer.

Joensuu H.

Cancer Treat Rev. 2017 Jan;52:1-11. doi: 10.1016/j.ctrv.2016.11.002. Epub 2016 Nov 10. Review.

16.

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

Berns K, Sonnenblick A, Gennissen A, Brohée S, Hijmans EM, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LF, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R.

Clin Cancer Res. 2016 Nov 1;22(21):5238-5248. Epub 2016 May 12.

PMID:
27172896
17.

Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort.

Fortner RT, Schock H, Kaaks R, Lehtinen M, Pukkala E, Lakso HÅ, Tanner M, Kallio R, Joensuu H, Korpela J, Toriola AT, Hallmans G, Grankvist K, Zeleniuch-Jacquotte A, Toniolo P, Lundin E, Surcel HM.

Cancer Res. 2017 Jan 1;77(1):134-141. doi: 10.1158/0008-5472.CAN-16-1524. Epub 2016 Oct 26.

PMID:
27784743
18.

Increased pancreatic cancer risk following radiotherapy for testicular cancer.

Hauptmann M, Børge Johannesen T, Gilbert ES, Stovall M, van Leeuwen FE, Rajaraman P, Smith SA, Weathers RE, Aleman BM, Andersson M, Curtis RE, Dores GM, Fraumeni JF Jr, Hall P, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Lynch CF, Pukkala E, Storm HH, Vaalavirta L, van den Belt-Dusebout AW, Morton LM, Fossa SD, Travis LB.

Br J Cancer. 2016 Sep 27;115(7):901-8. doi: 10.1038/bjc.2016.272. Epub 2016 Sep 6.

PMID:
27599043
19.

Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription.

Kaukonen R, Mai A, Georgiadou M, Saari M, De Franceschi N, Betz T, Sihto H, Ventelä S, Elo L, Jokitalo E, Westermarck J, Kellokumpu-Lehtinen PL, Joensuu H, Grenman R, Ivaska J.

Nat Commun. 2016 Aug 4;7:12237. doi: 10.1038/ncomms12237.

20.

Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.

Laurila JP, Laukkanen MO, Joensuu H, Salmi M, Jalkanen S.

Int J Cancer. 2016 Nov 15;139(10):2270-6. doi: 10.1002/ijc.30285. Epub 2016 Aug 11.

PMID:
27459381

Supplemental Content

Loading ...
Support Center